Literature DB >> 10523304

p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons.

K C Goh1, S J Haque, B R Williams.   

Abstract

Activation of cytosolic phospholipase A(2 )(cPLA(2)) is a prerequisite for the formation of the transcription factor complex interferon-stimulated gene factor 3 (ISGF3) in response to interferon-alpha (IFN-alpha). Here we show that p38 mitogen-activated protein kinase (MAPK), an activator of cPLA(2), is essential for both IFN-alpha and IFN-gamma signalling. SB203580, a specific inhibitor of p38, was found to inhibit ISGF3 formation but had no apparent effects on signal transducer and activator of transcription (STAT)1 homodimer formation. Regardless of this, the antiviral activities of both IFN-alpha and IFN-gamma were attenuated by SB203580. Treatment with either IFN led to rapid and transient activation of p38. Both IFNs induced STAT1 Ser727 phosphorylation, which was inhibited by SB203580 but not by an extracellular signal related kinase (ERK)1/2 inhibitor (PD98059). In an inducible 3T3-L1 clone, expression of dominant-negative p38 led to defective STAT1 serine phosphorylation and diminished IFN-gamma-mediated protection against viral killing. Reporter activity mediated by ISGF3 or STAT1 homodimer was diminished by SB203580 and enhanced by a constitutively active mutant of MKK6, the upstream activator of p38. Therefore, p38 plays a key role in the serine phosphorylation of STAT1 and transcriptional changes induced by both IFNs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523304      PMCID: PMC1171628          DOI: 10.1093/emboj/18.20.5601

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  92 in total

1.  Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferons.

Authors:  Andreas Pilz; Katrin Ramsauer; Hamid Heidari; Michael Leitges; Pavel Kovarik; Thomas Decker
Journal:  EMBO Rep       Date:  2003-03-21       Impact factor: 8.807

2.  Monocyte chemoattractant protein 1 regulates pulmonary host defense via neutrophil recruitment during Escherichia coli infection.

Authors:  Gayathriy Balamayooran; Sanjay Batra; Theivanthiran Balamayooran; Shanshan Cai; Samithamby Jeyaseelan
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

Review 3.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

4.  Sphingosine 1-phosphate-metabolizing enzymes control influenza virus propagation and viral cytopathogenicity.

Authors:  Young-Jin Seo; Celeste Blake; Stephen Alexander; Bumsuk Hahm
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 5.  Mitogen-activated protein kinase p38 in HIV infection and associated brain injury.

Authors:  Kathryn E Medders; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2011-02-01       Impact factor: 4.147

6.  p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation.

Authors:  Katrin Ramsauer; Iwona Sadzak; Almudena Porras; Andreas Pilz; Angel R Nebreda; Thomas Decker; Pavel Kovarik
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

7.  Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons.

Authors:  Ju-Tao Guo; Qing Zhu; Christoph Seeger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Filamin B serves as a molecular scaffold for type I interferon-induced c-Jun NH2-terminal kinase signaling pathway.

Authors:  Young Joo Jeon; Joon Seok Choi; Jung Yun Lee; Kyung Ryun Yu; Seung Hyeun Ka; Yongcheol Cho; Eui-Ju Choi; Sung Hee Baek; Jae Hong Seol; Dongeun Park; Ok Sun Bang; Chin Ha Chung
Journal:  Mol Biol Cell       Date:  2008-09-24       Impact factor: 4.138

9.  Tat engagement of p38 MAP kinase and IRF7 pathways leads to activation of interferon-stimulated genes in antigen-presenting cells.

Authors:  Nayoung Kim; Sami Kukkonen; Maria Del Pilar Martinez-Viedma; Sumeet Gupta; Anna Aldovini
Journal:  Blood       Date:  2013-03-27       Impact factor: 22.113

Review 10.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.